Cargando…

Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers

Immunotherapy has become the standard-of-care in many solid tumors. Despite the significant recent achievements in the diagnosis and treatment of cancer, several issues related to patients’ selection for immunotherapy remain unsolved. Multiple lines of evidence suggest that, in this setting, the vis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pagni, Fabio, Guerini-Rocco, Elena, Schultheis, Anne Maria, Grazia, Giulia, Rijavec, Erika, Ghidini, Michele, Lopez, Gianluca, Venetis, Konstantinos, Croci, Giorgio Alberto, Malapelle, Umberto, Fusco, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6862285/ https://www.ncbi.nlm.nih.gov/pubmed/31683784 http://dx.doi.org/10.3390/ijms20215452

Ejemplares similares

PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?
por: Fusco, Nicola, et al.
Publicado: (2020)

The molecular landscape of breast mucoepidermoid carcinoma
por: Venetis, Konstantinos, et al.
Publicado: (2023)

HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic Schemes
por: Ivanova, Mariia, et al.
Publicado: (2022)

Immune Biomarkers in Triple-Negative Breast Cancer: Improving the Predictivity of Current Testing Methods
por: Porta, Francesca Maria, et al.
Publicado: (2023)

Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization
por: Sajjadi, Elham, et al.
Publicado: (2021)

Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for PIK3CA Testing in HR+/HER2− Breast Cancer
por: Venetis, Konstantinos, et al.
Publicado: (2022)

The Role of the Pathologist in the Next-Generation Era of Tumor Molecular Characterization
por: Angerilli, Valentina, et al.
Publicado: (2021)

Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test
por: Sajjadi, Elham, et al.
Publicado: (2023)

Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors
por: Indini, Alice, et al.
Publicado: (2021)

Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling
por: Sajjadi, Elham, et al.
Publicado: (2021)

HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
por: Venetis, Konstantinos, et al.
Publicado: (2022)

Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record
por: Pagni, Fabio, et al.
Publicado: (2020)

Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review
por: Indini, Alice, et al.
Publicado: (2021)

Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management
por: Ivanova, Mariia, et al.
Publicado: (2023)

Neoadjuvant Chemo-Immunotherapy for Locally Advanced Non-Small-Cell Lung Cancer: A Review of the Literature
por: Franzi, Sara, et al.
Publicado: (2022)

Do we need elastography for EUS?
por: Dietrich, Christoph F., et al.
Publicado: (2020)

FFPE-Based NGS Approaches into Clinical Practice: The Limits of Glory from a Pathologist Viewpoint
por: Cappello, Filippo, et al.
Publicado: (2022)

Pulmonary nodules: do we need a separate algorithm for non-solid lesions?
por: Diederich, S.
Publicado: (2009)

Controversies in EUS: Do we need miniprobes?
por: Seifert, Hans, et al.
Publicado: (2021)

Osteoclast-like stromal giant cells in breast cancer likely belong to the spectrum of immunosuppressive tumor-associated macrophages
por: Sajjadi, Elham, et al.
Publicado: (2022)

Commentary: Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients
por: Venetis, Konstantinos, et al.
Publicado: (2021)

Do we need contrast agents for EUS?
por: Saftoiu, Adrian, et al.
Publicado: (2020)

Editorial: Diagnosis and Treatment of Breast Cancer in 2022: The Rise of Novel Molecular Biomarkers
por: Fusco, Nicola, et al.
Publicado: (2023)

Why do we Need Quality Articles, What are we Going to do With?
por: Mueen Ahmed, KK
Publicado: (2011)

When do we need to do meta-analysis!!!
por: Soni, Kapil D.
Publicado: (2023)

Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors
por: Indini, Alice, et al.
Publicado: (2021)

Do we still need supertrees?
por: Haeseler, Arndt von
Publicado: (2012)

Do we need an SBIRT program?
por: Pelayo, Hugo López, et al.
Publicado: (2013)

Do We Need Psychiatric Hospitals?
por: Whitehead, Anthony, et al.
Publicado: (1969)

Do We Serve a Need?
por: Somberg, John
Publicado: (2021)

Do we need attentional suppression?
por: Kerzel, Dirk, et al.
Publicado: (2021)

Syncope—Do We Need AI?
por: Olshansky, Brian, et al.
Publicado: (2023)

Anti-Claudin Treatments in Gastroesophageal Adenocarcinoma: Mainstream and Upcoming Strategies
por: Grizzi, Giulia, et al.
Publicado: (2023)

Impact of Use of Gastric-Acid Suppressants and Oral Anti-Cancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis
por: Indini, Alice, et al.
Publicado: (2020)

Editorial: Cancer diagnostics in solid tumors-from pathology to precision oncology
por: Malapelle, Umberto, et al.
Publicado: (2023)

Do we harm others even if we don't need to?
por: Cacault, M. Paula, et al.
Publicado: (2015)

In a search of a protective titer: Do we or do we not need to know?
por: Baranova, Ancha, et al.
Publicado: (2021)

Do we really need another risk prediction rule? Yes, we do
por: Lo, Alexander X., et al.
Publicado: (2022)

Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema
por: Invernizzi, Marco, et al.
Publicado: (2020)

Teleneurorehabilitation in the COVID-19 Era: What Are We Doing Now and What Will We Do Next?
por: Calabrò, Rocco Salvatore
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cratpuvnp38pdb9gurlnpk8bdb